News Lundbeck Nasdaq Copenhagen

Equities

LUN

DK0061804697

Real-time Estimate Cboe Europe Other stock markets 08:00:58 2024-05-14 am EDT			5-day change	1st Jan Change
30.25 ^DKK	0.00%		+4.31%	-12.42%

May. 13	H LUNDBECK : Lundbeck is well-poised to sail through the transition period
May. 13	H. Lundbeck A/S Appoints Announces the Appointment of Maria Alfaiate as EVP, Commercial and Corporate Strategy, Effective 1 August 2024	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

H LUNDBECK : Lundbeck is well-poised to sail through the transition period	May. 13
Maria Alfaiate appointed new Executive Vice President Commercial and Corporate Strategy at Lundbeck	May. 13	AQ
H. Lundbeck A/S Appoints Announces the Appointment of Maria Alfaiate as EVP, Commercial and Corporate Strategy, Effective 1 August 2024	May. 13	CI
H. Lundbeck, Otsuka Pharmaceutical Seek US FDA Nod for PTSD Combination Therapy	Apr. 09	MT
Lundbeck and Otsuka submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD	Apr. 09	AQ
Lundbeck and Otsuka submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD	Apr. 09	CI
Lundbeck : Articles of Association	Apr. 02	PU
EU Commission Green-lights Lundbeck, Otsuka's Abilify Maintena as Maintenance Treatment of Schizophrenia	Mar. 27	MT
Abilify Maintena[®] 960 mg (aripiprazole) approved in the EU as the first once-every-two-months long-acting injectable for the maintenance treatment of schizophrenia	Mar. 27	AQ
Otsuka Pharmaceutical Europe Ltd. and H. Lundbeck A/S Announces Approval in the EU for the Maintenance Treatment of Schizophrenia	Mar. 27	CI
Lundbeck held its Annual General Meeting on 20 March 2024 at the company's registered office	Mar. 20	AQ
H. Lundbeck A/S Announces Management Appointments	Mar. 20	CI
H. Lundbeck A/S Approves Dividend for the Accounting Year 2023	Mar. 20	CI
Transcript : H. Lundbeck A/S - Shareholder/Analyst Call	Mar. 20
H. Lundbeck Plans Clinical Development of Migraine Prevention Drug	Mar. 15	MT
Lundbeck's potential first-in-class therapy for migraine prevention enters advanced clinical stage	Mar. 15	AQ
H. Lundbeck A/S Announces Potential First-In-Class Therapy for Migraine Prevention Enters Advanced Clinical Stage	Mar. 15	CI
Lundbeck presents encouraging results from the Lu AF82422 trial for Multiple System Atrophy at the international AD/PD 2024 conference on neurodegenerative disorders	Mar. 05	AQ
Notice of Annual General Meeting	Feb. 23	AQ
H. Lundbeck A/S Proposes Dividend for the Accounting Year 2023	Feb. 23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

H LUNDBECK : Lundbeck is well-poised to sail through the transition period

May 13, 2024 at 11:18 am EDT